Curis, Inc. CRIS
Regular-session close
After hours · Nov 20, 4:38 PM ET
- YTD
- -97.84%
- 1 year
- -98.02%
5D +0.0080 (+1.90%)
- Market cap
- 4.06M
- Revenue (ttm)
- 10.16M
- EPS (ttm)
- 15.43
- Shares out
- 8.47M
- P/E ratio
- 0.03
- Forward P/E
- -0.77
- YTD return
- -97.84%
- 1-year return
- -98.02%
- 50-day average
- 4.30
- Volume
- 520.05K
- Avg volume
- 4.33M
- Open
- 0.471
- Previous close
- 0.4694
- Day's range
- 0.42 – 0.4936
- 52-week range
- 0.33 – 28.40
- Beta
- 3.35
- Analysts
- Buy
- Price target
- 21.00 (+4818.0%)
Key statistics
- 200-day average
- 7.78
- Enterprise value
- 37.35M
- Price / sales
- 2.71
- Price / book
- 0.97
- Revenue growth
- 15.90%
- Free cash flow
- -25.84M
- Total cash
- 28.36M
- Total debt
- 41.92M
- Return on equity
- -372.68%
- Short % of float
- 2.28%
Fundamental scorecard
5 of 25 checks passed on CRIS’s reported financials
5of 25 checks passed
- Value 2 of 5
- Growth 1 of 5
- Profitability 0 of 5
- Financial health 2 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 13, 2025 | Dec 1, 2024 | -1.36 | — | — | — |
| Nov 14, 2024 | Sep 1, 2024 | -1.88 | -1.70 | +0.18 | +9.57% |
| Aug 1, 2024 | Jun 1, 2024 | -1.70 | -2.03 | -0.33 | -19.41% |
| May 7, 2024 | Mar 1, 2024 | -1.94 | -2.05 | -0.11 | -5.67% |
| Feb 8, 2024 | Dec 1, 2023 | -1.91 | -2.03 | -0.12 | -6.28% |
| Nov 2, 2023 | Sep 1, 2023 | -2.32 | -2.13 | +0.19 | +8.19% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 10, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Nov 15, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Nov 1, 2024 | HC Wainwright & Co. | main | Buy | Buy |
| Aug 1, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| May 15, 2024 | Truist Securities | main | Buy | Buy |
| May 15, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
About Curis, Inc.
Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes. The company's pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma; CA-170, an oral, small molecule antagonist designated as CA-170 that selectively targets PD-L1 and VISTA; and CA-327, an oral, small molecule, TIM3/PD-L1, which is a molecule antagonist of PD-L1 and TIM3. It has collaboration agreement with Genentech Inc., or Genentech and F. Hoffmann-La Roche Ltd, or Roche, for the commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway antagonist for the treatment of advanced basal cell carcinoma, or BCC; Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology; and also licensed four programs under the Aurigene collaboration, including emavusertib. Curis, Inc. was incorporated in 2000 and is headquartered in Lexington, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- curis.com
News
12 Health Care Stocks Moving In Wednesday's After-Market Session
Why Pony AI Shares Are Trading Higher By Over 10%; Here Are 20 Stocks Moving Premarket HC Wainwright & Co. Maintains Buy on Curis, Lowers Price Target to $6
Curis Q3 EPS $(1.94) Beats $(2.01) Estimate
12 Health Care Stocks Moving In Wednesday's After-Market Session
12 Health Care Stocks Moving In Wednesday's Intraday Session
Dow Jumps Over 1,100 Points; McDonald’s Shares Gain Following Upbeat Earnings
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Why Limbach Holdings Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket
12 Health Care Stocks Moving In Tuesday's Intraday Session
Your note
Sign in to keep a note on CRIS — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Maverick Capital Ltd. | 6.88% | 582,273 | 1.89M | Sep 29, 2024 |
| M28 Capital Management LP | 4.98% | 421,951 | 1.37M | Sep 29, 2024 |
| Vanguard Group Inc | 3.24% | 274,681 | 892.71K | Sep 29, 2024 |
| CM Management, LLC | 1.42% | 120,000 | 390.00K | Sep 29, 2024 |
| Renaissance Technologies, LLC | 1.11% | 93,772 | 304.76K | Sep 29, 2024 |
| Citigroup Inc. | 1.09% | 91,872 | 298.58K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.19% | 185,441 | 602.68K | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 0.96% | 81,339 | 264.35K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.40% | 33,521 | 108.94K | Oct 30, 2024 |
| iShares Micro Cap ETF | 0.16% | 13,425 | 43.63K | Oct 30, 2024 |
| Northern Small Cap Core Fund | 0.14% | 11,800 | 38.35K | Sep 29, 2024 |
| Fidelity Total Market Index Fund | 0.12% | 10,208 | 33.18K | Oct 30, 2024 |
